Mezigdomide not checked

Celgene · BMS-986348 · CC-92480

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
10 active
17 in total · 10 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Multiple Myeloma (5 trials), Relapsed or Refractory Multiple Myeloma (2 trials)
Main trialPhase 3
“The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.”In the company’s words, NCT05552976 on ClinicalTrials.gov
Other names
BMS-986348 · CC-92480

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 28 Sep 2026 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Phase 3Recruiting 10 Jan 2027 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1/2Recruiting 12 Oct 2026 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2Active, not recruiting 30 Nov 2026 A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Phase 1/2Recruiting Apr 2027 Selinexor and Backbone Treatments of Multiple Myeloma Patients
Phase 1/2Recruiting 31 May 2027 A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1Recruiting 1 Aug 2028 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2Terminated 20 Aug 2025 A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 1Completed 13 May 2021 A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
Phase 1Completed 8 Oct 2021 A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
Phase 1Completed 12 Nov 2022 A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
Phase 1Completed 13 Sep 2023 A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
Phase 1Completed 15 Nov 2024 A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
Phase 1Terminated 3 Jun 2025 A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 2Authorised not given A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)
Phase 2Authorised not given A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
Phase 2Authorised not given Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mezigdomide

Following is part of Solo: you see every change to Mezigdomide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in